Long Jiang

Long Jiang

Auto-generated profile, based on publicly available information

Long Jiang

Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Science Advances
Verified
Journal Article
Open access
HMHui Ma
Hui Ma
TLTao Li
Tao Li
XXXuefeng Xie
Xuefeng Xie
LJLong Jiang
Long Jiang
JYJingwei Ye
Jingwei Ye
Qinghua ShiQinghua Shi
Qinghua Shi
RAD51AP2 is required specifically for efficient meiotic recombination to form crossover between X and Y chromosomes.

24 December 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
JGJianing Gao
Jianing Gao
HZHuan Zhang
Huan Zhang
XJXiaohua Jiang
Xiaohua Jiang
AAAsim Ali
Asim Ali
DZDaren Zhao
Daren Zhao
YZYuanwei Zhang
Yuanwei Zhang
Exploring the genetic basis of human infertility is currently under intensive investigation. However, only a handful of genes have been validated in animal models as disease-causing genes in infertile men. Thus, to better understand the genetic basis of human spermatogenesis and bridge the knowledge gap between humans and other animal species, we construct the FertilityOnline, a database integrating the literature-curated functional genes during spermatogenesis into an existing spermatogenic database, SpermatogenesisOnline 1.0. Additional features, including the functional annotation and genetic variants of human genes, are also incorporated into FertilityOnline. By searching this database, users can browse the functional genes involved in spermatogenesis and instantly narrow down the number of candidates of genetic mutations underlying male infertility in a user-friendly web interface. Clinical application of this database was exampled by the identification of novel causative mutations in synaptonemal complex central element protein 1 (SYCE1) and stromal antigen 3 (STAG3) in azoospermic men. In conclusion, FertilityOnline is not only an integrated resource for spermatogenic genes but also a useful tool facilitating the exploration of the genetic basis of male infertility. FertilityOnline can be freely accessed at http://mcg.ustc.edu.cn/bsc/spermgenes2.0/index.html.

17 December 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
VVVictoria M. Valvo
Victoria M. Valvo
QZQiang Zhang
Qiang Zhang
LJLong Jiang
Long Jiang
EHErin A. Holcomb
Erin A. Holcomb
APAshley N. Pearson
Ashley N. Pearson
MMMeredith A. Morgan
Meredith A. Morgan
PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)–mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy. To test this hypothesis, we assessed the effects of olaparib and radiation on T1IFN production and sensitivity to αPD-L1 immunotherapy, as well as on the tumor microenvironment by single-cell RNA sequencing. We found that olaparib enhanced T1IFN production after radiation and had superior therapeutic efficacy in immunocompetent models. Olaparib and radiation treatment sensitized PDAC tumors to αPD-L1, resulting in decreased tumor burden and a 33% complete response rate. Combination treatment provided durable immune responses as shown by tumor rejection upon tumor rechallenge of previously cured mice. Furthermore, single-cell RNA sequencing analysis revealed that combination treatment induced an immunogenic tumor microenvironment characterized by interferon (IFN) responses in both PDAC and myeloid cell populations, macrophage polarization, and increased CD8+ terminal effector T-cell frequency and activity, findings which were confirmed by IHC and flow cytometry. Furthermore, CD8+ T cells and T1IFN signaling were required for therapeutic efficacy as host depletion of CD8+ T cells or the T1IFN receptor diminished treatment responses. Overall, our results indicate that olaparib enhances radiation-induced T1IFN-mediated immune signaling and subsequently an adaptive immune response, thus sensitizing pancreatic cancer to αPD-L1 therapy, supporting an ongoing clinical trial of this therapy in patients with PDAC. See related commentary by Buchsbaum, p. 840

4 June 2025
Verified
Other
Open access
PDF file
VVVictoria M. Valvo
Victoria M. Valvo
QZQiang Zhang
Qiang Zhang
LJLong Jiang
Long Jiang
EHErin A. Holcomb
Erin A. Holcomb
APAshley N. Pearson
Ashley N. Pearson
MMMeredith A. Morgan
Meredith A. Morgan
Supplemental Figure 4. (A-D) Workflow of CD8+ T cell isolation. All T cells (excluding cycling T cells) were isolated (A) and CD8+, CD4+, and NK status was determined (B). CD8+ T cells were further isolated and clustered (C). CD8+ only status was confirmed via violin plots of Cd8a, Cd4, and Fcer1g (D). (E) UMAP projection of CD8+ T cell clusters split by treatment group. (F) Bar plot displaying the percentage of total cells sequenced identified as B cells. (G) GSEAplots of important pathways found to be enriched in CD8+ T cell comparisons following GSEA including interferon alpha response, interferon gamma response, IL2/STAT5 signaling, and G2M checkpoint for the comparison between olaparib+radiation+αPD-L1 CD8+ T cells and radiation+αPD-L1 CD8+ T cells.

4 June 2025
Verified
Other
Open access
PDF file
VVVictoria M. Valvo
Victoria M. Valvo
QZQiang Zhang
Qiang Zhang
LJLong Jiang
Long Jiang
EHErin A. Holcomb
Erin A. Holcomb
APAshley N. Pearson
Ashley N. Pearson
MMMeredith A. Morgan
Meredith A. Morgan
Supplemental Figure 2. (A) Tumor growth inhibition analysis for Figure 2A conducted on day 13. Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. Mean tumor volume (MTV) ± standard deviation (SD) are denoted for each treatment group along with the calculated percent tumor growth inhibition (%TGI). (B) C57BL/6 mice with subcutaneous mT4 tumors were treated with αPD-L1 pre-, concurrent, or post-olaparib and radiation treatment. The different schedules are concurrent treatment with αPD-L1 (olaparib on days 1-5, and 8-12; radiation on day 1; αPD-L1 treatment on days 0 and 3), pre-treatment with αPD-L1 (olaparib on days 7-11 and 14-18; radiation on day 7; αPD-L1 treatment on days 0 and 3) and post-treatment with αPD-L1 (olaparib on days 0-4 and 7-11; radiation on day 0; αPD-L1 treatment on days 7 and 10). Data represent mean tumor volumes ± SEM from n= 10 (IgG), 20 (concurrent treatment), 20 (pre-treatment), and 20 (post-treatment) tumors per treatment group. (C) Serum was collected for each treatment condition on day 15 from 3 mice undergoing treatment in panel B. Complete blood cell count was conducted at the University of Michigan by the Unit for Laboratory Animal Medicine (RRID: SCR_025790) using a Heska HT5 Element. Percentage of white blood cells and lymphocytes from total serum are shown. (D) Tumor growth inhibition analysis for Figure 2B conducted on day 13. Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI. (E) Mouse weights monitored throughout treatment with olaparib, radiation, and αPD-L1. This data is from mice used Figure 2F. Data represent the average mouse weight (g) ± SEM from n= 6 (IgG), 7 (αPD-L1), 6 (olaparib+IgG), 7 (olaparib+αPD-L1), 8 (RT+IgG), 10 (RT+αPD-L1), 7 (olaparib+RT+IgG) and 9 (olaparib+RT+αPD-L1) mice per treatment group. (F) Individual tumor growth curves from mice used in Figure 2F. Data are represented as tumor volume and show n= 6 (IgG), 7 (αPD-L1), 6 (olaparib+IgG), 7 (olaparib+αPD-L1), 8 (RT+IgG), 10 (RT+αPD-L1), 7 (olaparib+RT+IgG), and 9 (olaparib+RT+αPD-L1) tumors per treatment group. (G, H) Tumor growth inhibition analysis for Figure 2D conducted on day 31 (G) and Figure 2F conducted on day 44 (H). Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI.

4 June 2025
Verified
Other
Open access
PDF file
VVVictoria M. Valvo
Victoria M. Valvo
QZQiang Zhang
Qiang Zhang
LJLong Jiang
Long Jiang
EHErin A. Holcomb
Erin A. Holcomb
APAshley N. Pearson
Ashley N. Pearson
MMMeredith A. Morgan
Meredith A. Morgan
Supplemental Figure 6. (A, B) Tumor growth inhibition analysis for Figure 6A conducted on day 42 (A) and Figure 6C conducted on day 32 (B). Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI.